Oettgen H F, Old L J, Farrow J H, Valentine F T, Lawrence H S, Thomas L
Proc Natl Acad Sci U S A. 1974 Jun;71(6):2319-23. doi: 10.1073/pnas.71.6.2319.
Five patients with advanced breast cancer were treated with pooled dialyzable transfer factor from healthy adult donors. The period of treatment ranged from 21 to 310 days, the total dose from 20 to 257 ml. Transfer factor did not elicit inflammatory or hypersensitivity reactions or detectable formation of antibody to itself, nor any hematological or biochemical abnormalities or other side effects. Three patients became responsive (by skin test) to tuberculin and/or streptococcal antigens. Marked partial regression of the breast cancer, lasting 6 months, was observed in one patient.
5例晚期乳腺癌患者接受了来自健康成年供者的混合可透析转移因子治疗。治疗期为21至310天，总剂量为20至257毫升。转移因子未引发炎症或过敏反应，未检测到自身抗体形成，也未出现任何血液学或生化异常及其他副作用。3例患者（通过皮肤试验）对结核菌素和/或链球菌抗原有反应。1例患者出现乳腺癌明显部分消退，持续6个月。
